Fuchs Dystrophy - Pipeline Insight, 2024

This “Fuchs Dystrophy - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Fuchs Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Fuchs Dystrophy Understanding

Fuchs Dystrophy: Overview

Fuchs’ dystrophy is a genetic disease affecting the cornea. Although a patient is born with the condition, it is not detectable or symptomatic until middle age or later. During the disease’s progression, the layer of cells (endothelium) responsible for maintaining proper fluid levels in the cornea will deteriorate and cause tiny bumps (guttae) to form on the back of the cornea. When enough cells are lost, fluid builds up in the cornea, resulting in swelling. This swelling, called corneal edema, causes clouding or blurring of vision. One of the first signs of Fuchs’ dystrophy is blurred vision, caused by fluid buildup in the cornea. In early stages of the disease, the excess fluid builds up overnight during sleep, causing blurry vision and/or discomfort when waking in the morning. This may last for hours. The excess fluid can be drawn out of the cornea over the course of the day, reducing the swelling and improving vision. While current therapies cannot reverse Fuchs' dystrophy, early stages of the disease may be treated with nonsurgical solutions such as eyedrops or eye ointment. Patients with Fuchs’ dystrophy may also develop cataracts (link to cataract HL). In cases of mild or moderate Fuchs’ severity with cataracts, cataract surgery may be the only recommended treatment.

Fuchs Dystrophy - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fuchs Dystrophy pipeline landscape is provided which includes the disease overview and Fuchs Dystrophy treatment guidelines. The assessment part of the report embraces, in depth Fuchs Dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fuchs Dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Fuchs Dystrophy.
• In the coming years, the Fuchs Dystrophy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Fuchs Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Fuchs Dystrophy treatment market. Several potential therapies for Fuchs Dystrophy are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Fuchs Dystrophy market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Fuchs Dystrophy) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Fuchs Dystrophy Emerging Drugs Chapters

This segment of the Fuchs Dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fuchs Dystrophy Emerging Drugs

K-321: Kowa Pharmaceutical Ripasudil (K-321) is a rho-kinase inhibitor. Rho-associated protein kinase (ROCK) is a protein which regulates the shape and movement of cells in a number of tissues, including the eye. K-321 is a different formulation of ripasudil from Glanatec and if it has the same effects on corneal endothelial cells in the eye as it does on cells in culture, may prove to be a novel potential treatment for Fuch’s endothelial corneal dystrophy (FECD). It is currently under investigation to be used as an adjunct to healing following Descemet Stripping Only (DSO) surgery as a treatment forFECD.

TTHX1114: Trefoil Therapeutics TTHX1114 is an engineered form of the naturally occurring molecule Fibroblast Growth Factor-1 (FGF-1), which stimulates cell proliferation and migration as well as protects cells from stress and injury. TTHX1114 has been engineered to increase FGF-1’s longevity in the eye, enabling its use as a pharmaceutical. The study is sponsored by San Diego-based Trefoil Therapeutics, a private biotechnology company developing therapeutics for corneal diseases.

Fuchs Dystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Fuchs Dystrophy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Fuchs Dystrophy

There are approx. 5+ key companies which are developing the therapies for Fuchs Dystrophy. The companies which have their Fuchs Dystrophy drug candidates in the most advanced stage, i.e. phase II include, Kowa Pharmaceutical.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Fuchs Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fuchs Dystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fuchs Dystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fuchs Dystrophy drugs.

Fuchs Dystrophy Report Insights

• Fuchs Dystrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fuchs Dystrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fuchs Dystrophy drugs?
• How many Fuchs Dystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fuchs Dystrophy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fuchs Dystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Fuchs Dystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kowa Pharmaceutical
• Trefoil Therapeutics
• Aerie Pharmaceuticals
• Santen Inc.
• Emmecell
• Surrozen
• Design Therapeutics
• ActualEyes

Key Products

• K-321
• TTHX1114
• Netarsudil mesylate
• STN1010904
• EO2002
• FECD Gene TAC™ smallmolecules
• AE 101
• AE 002

This product will be delivered within 2 business days.